Site Menu

Our Story

From research to revolution

Aprecia Pharmaceuticals was founded in 2003 with the explicit goal of achieving commercial production for unique pharmaceutical dosage forms via advanced three-dimensional printing (3DP) technology.

Powder-liquid 3DP, a novel technology that forms objects layer by layer, was originally developed at the Massachusetts Institute of Technology (MIT) in the late 1980s as a rapid-prototyping technique. From 1993 to 2003, this work was expanded into the distinct areas of tissue engineering and pharmaceuticals. While 3DP technology rights were licensed for a diverse range of industrial fields, MIT's 3DP process and its applications in the pharmaceutical industry are exclusively licensed to Aprecia.

In 2007, we began developing our orodispersible platform, known as ZipDose® Technology. ZipDose® formulations bring easy-to-swallow functionality to high-dose medications, overcoming challenges unaddressed by prior technologies. Our vision: to enhance patients' experience with highly prescribed high-dose medications.

In 2008, Aprecia began working with a proprietary forming system that enhances manufacturing efficiency and output in the 3DP process. This enabled us to achieve our initial goal of reaching commercial production for our 3DP formulations. This initiative continued through 2011, when we further refined this process to prepare for commercialization of the 3DP and ZipDose® Technology platform in a cGMP facility.

In 2011, Aprecia also began operations at our facility in East Windsor, NJ.

In 2015, Aprecia's first 3D printed drug product was approved by the FDA.

Aprecia continues to add manufacturing capacity and additional sites to support our expanding product pipeline and enhance our commercial capacity.

Key Milestones